Prostate Medication, Metabolism and Gut Microbiota

Launched by TURKU UNIVERSITY HOSPITAL · Aug 17, 2023

Keywords

ClinConnect Summary

The PROMED trial is a research study that looks at how certain prostate medications might affect the gut bacteria and overall metabolism in men. The main focus is on understanding how prostate hormonal therapies, like dutasteride and finasteride, change the composition of gut microbiota, which are the tiny organisms living in our intestines. The study also aims to see how these gut bacteria influence how well patients respond to their medications. This trial is taking place at Turku University Hospital and is open to men aged 65 to 74 who are willing to follow the study procedures and provide consent.

To participate, candidates must not have had recent gastrointestinal issues, such as gastroenteritis or antibiotic treatments, and they should not have undergone fecal transplantation. If eligible, participants can expect to receive specific prostate medications as part of the study and will be monitored over time. The findings could help improve treatment strategies for men with prostate conditions by shedding light on the connection between medications and gut health.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Provision of signed and dated informed consent form.
• • Ability and stated willingness to comply with all study procedures and availability for the duration of the study.
• Exclusion Criteria:
• • Any history of a fecal transplantation.
• • Recent (within 3 months or still symptomatic) gastroenteritis.
• • Antibiotic treatment within 3 months (expect for antibiotic prophylaxis related to prostate biopsies).
• • Inability to comply with the protocol of unwillingness to participate in the study.